-
公开(公告)号:US20120101126A1
公开(公告)日:2012-04-26
申请号:US13280431
申请日:2011-10-25
IPC分类号: A61K31/47 , C07D215/14
CPC分类号: C07D215/14 , C07B2200/13
摘要: The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.
摘要翻译: 本发明涉及匹伐他汀半钙盐的新结晶形式,以下称为多晶型A,B,C,D,E和F,以及无定形形式。 此外,本发明涉及制备这些结晶形式的方法和包含这些结晶形式或无定形形式的无定形形式和药物组合物。
-
公开(公告)号:US20080269315A1
公开(公告)日:2008-10-30
申请号:US12080141
申请日:2008-03-31
IPC分类号: A61K31/40 , C07D207/30
CPC分类号: C07D207/34
摘要: The present invention is directed to the novel polymorphic Form F of Atorvastatin calcium, processes for the preparation thereof and pharmaceutical compositions comprising this crystalline form.
摘要翻译: 本发明涉及阿托伐他汀钙的新型多晶型F,其制备方法和包含该结晶形式的药物组合物。
-
公开(公告)号:US20080249149A1
公开(公告)日:2008-10-09
申请号:US10585448
申请日:2005-01-05
申请人: Paul Adriaan Van Der Schaaf , Jorg Berghausen , Fritz Blatter , Martin Szelagiewicz , Ulrich Berens
发明人: Paul Adriaan Van Der Schaaf , Jorg Berghausen , Fritz Blatter , Martin Szelagiewicz , Ulrich Berens
IPC分类号: A61K31/41 , C07D249/08 , A61P25/06 , A61K31/135
CPC分类号: C07D403/06
摘要: The present invention is directed to the novel polymorphic Form A and Form B of Rizatriptan benzoate, processes for the preparation thereof and pharmaceutical compositions comprising these crystalline forms.
摘要翻译: 本发明涉及利多曲坦苯甲酸酯的新型多晶型A和B型,其制备方法和包含这些结晶形式的药物组合物。
-
公开(公告)号:US20080194604A1
公开(公告)日:2008-08-14
申请号:US11883008
申请日:2006-01-23
IPC分类号: A61K31/505 , C07D239/42
CPC分类号: C07D239/42
摘要: Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] (also known as rosuvastatin) calcium salt and hydrates can exist in new crystal forms B and C. These crystal forms provide a higher diversity on crystalline materials to optimize manufacture, formulation and biological efficiency.
摘要翻译: 双[(E)-7- [4-(4-氟苯基)-6-异丙基-2- [甲基(甲基磺酰基)氨基]嘧啶-5-基] - (3R,5S)-3,5-二羟基庚-6- - 烯酸](也称为瑞舒伐他汀)钙盐和水合物可以以新的晶型B和C存在。这些晶体形式在结晶材料上提供更高的多样性以优化制造,配制和生物效率。
-
公开(公告)号:US07932387B2
公开(公告)日:2011-04-26
申请号:US11883008
申请日:2006-01-23
IPC分类号: C07D239/42 , A61K31/505 , A61P3/06
CPC分类号: C07D239/42
摘要: Bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid] (also known as rosuvastatin) calcium salt and hydrates can exist in new crystal forms B and C. These crystal forms provide a higher diversity on crystalline materials to optimize manufacture, formulation and biological efficiency.
摘要翻译: 双[(E)-7- [4-(4-氟苯基)-6-异丙基-2- [甲基(甲基磺酰基)氨基]嘧啶-5-基] - (3R,5S)-3,5-二羟基庚-6- - 烯酸](也称为瑞舒伐他汀)钙盐和水合物可以以新的晶型B和C存在。这些晶体形式在结晶材料上提供更高的多样性以优化制造,配制和生物效率。
-
公开(公告)号:US07777049B2
公开(公告)日:2010-08-17
申请号:US10585448
申请日:2005-01-05
申请人: Paul Adriaan Van Der Schaaf , Jörg Berghausen , Fritz Blatter , Martin Szelagiewicz , Ulrich Berens
发明人: Paul Adriaan Van Der Schaaf , Jörg Berghausen , Fritz Blatter , Martin Szelagiewicz , Ulrich Berens
IPC分类号: C07D401/12
CPC分类号: C07D403/06
摘要: The present invention is directed to the novel polymorphic Form A and Form B of Rizatriptan benzoate, processes for the preparation thereof and pharmaceutical compositions comprising these crystalline forms.
摘要翻译: 本发明涉及利多曲坦苯甲酸酯的新型多晶型A和B型,其制备方法和包含这些结晶形式的药物组合物。
-
公开(公告)号:US20090281162A1
公开(公告)日:2009-11-12
申请号:US12386413
申请日:2009-04-17
IPC分类号: A61K31/40 , C07D207/34
CPC分类号: C07D207/34
摘要: The present invention is directed to new crystalline forms of Atorvastatin calcium (2:1), referred to hereinafter as polymorphic Forms X, A, B1, B2, C, D and E. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms.
-
公开(公告)号:US07432380B2
公开(公告)日:2008-10-07
申请号:US10576784
申请日:2004-10-06
IPC分类号: C07D209/12
CPC分类号: C07D209/24
摘要: A novel crystalline form of Fluvastatin sodium hydrate is described, referred to hereinafter as polymorphic Form G. Furthermore, processes for the preparation of this crystalline form and pharmaceutical compositions comprising this crystalline form are reported.
摘要翻译: 描述了氟伐他汀钠水合物的新型结晶形式,下文称为多晶型G.此外,报道了制备该结晶形式的方法和包含该结晶形式的药物组合物。
-
公开(公告)号:US20090057613A1
公开(公告)日:2009-03-05
申请号:US11630488
申请日:2005-06-20
IPC分类号: C09K11/06 , C07D471/04 , G01N21/64
CPC分类号: H05B33/14 , C07D471/04 , C09K11/06 , C09K2211/1044 , H01L51/0052 , H01L51/0053 , H01L51/0062 , H01L51/0071 , H01L51/0072 , H01L51/0081 , H01L2251/308
摘要: The present invention relates to compounds of the Formula (I), a process for their preparation and their use for the preparation of inks, colorants, pigmented plastics, coatings, non-impact-printing material, color filters, cosmetics, polymeric ink particles, toners, as fluorescent tracers, in color changing media, in solid dye lasers and electroluminescent devices. A luminescent device comprising a composition according to the present invention is high in the efficiency of electrical energy utilisation and high in luminance.
摘要翻译: 本发明涉及式(I)的化合物,其制备方法及其用于制备油墨,着色剂,着色塑料,涂料,非冲击印刷材料,滤色器,化妆品,聚合物油墨颗粒, 调色剂,荧光示踪剂,变色介质,固体染料激光器和电致发光器件。 包含根据本发明的组合物的发光装置的电能利用效率高,亮度高。
-
公开(公告)号:US07402675B2
公开(公告)日:2008-07-22
申请号:US10919776
申请日:2004-08-17
申请人: Andreas Hafner , Hans Jürg Kirner , Franz Schwarzenbach , Paul Adriaan Van Der Schaaf , Peter Nesvadba
发明人: Andreas Hafner , Hans Jürg Kirner , Franz Schwarzenbach , Paul Adriaan Van Der Schaaf , Peter Nesvadba
IPC分类号: C07D211/54
CPC分类号: C07D401/14 , C04B35/632 , C07D209/44 , C07D211/94 , C07D217/26 , C07D241/08 , C07D401/12 , C07D405/12 , C08K5/3412
摘要: An amine ether of formula A wherein a is 1 or 2; and when a is 1, E is E′; when a is 2, E is L; E′ is C1-C36 alkyl; C3-C18 alkenyl; C2-C18 alkinyl; C5-C18 cycloalkyl; C5-C18 cycloalkenyl; a radical of a saturated or unsaturated aliphatic bicyclic or tricyclic hydrocarbon of 7 to 12 carbon atoms; C2-C7alkyl or C3-C7alkenyl substituted by halogen; C7-C15 aralkyl or C7-C15 aralkyl substituted by C1-C4 alkyl or phenyl; or E′ is a radical of formula (VII) as explained in claim 1; T′ is tertiary C4-C18alkyl or phenyl, each of which are unsubstituted or substituted by halogen, OH, COOR21 or C(O)—R22; or T′ is C5-C12cycloalkyl; C5-C12cycloalkyl which is interrupted by at least one O or —NR18—; a polycyclic alkyl radical having 7-18 carbon atoms, or the same radical which is interrupted by at least one O or —NR18—; or T′ is —C(G1)(G2)-T″; or C1-C18alkyl or C5-C12cycloalkyl substituted by T″ is hydrogen, halogen, NO2, cyano, or is a monovalent organic radical comprising 1-50 carbon atoms; or T″ and T′ together form a divalent organic linking group completing, together with the hindered amine nitrogen atom and the quaternary carbon atom substituted by G1 and G2, an optionally substituted five- or six-membered ring structure; and all other residues are as defined in claim 1, are obtained in good yield from the corresponding N-oxyl hindered amine precursor by reaction with a hydrocarbon E1-H or H-L-H in the presence of an organic hydroperoxide and a catalytic amount of copper or a copper compound. The products of present process find utility as polymerization regulators and/or light stabilizers for organic material.
-
-
-
-
-
-
-
-
-